Discovery of novel inhibitors of the NorA multidrug transporter of staphylococcus aureus

Journal of Medicinal Chemistry

Volumn 54, Issue 1, 2011, Pages 354-365

  Brincat, Jean Pierre ^a   Carosati, Emanuele ^a   Sabatini, Stefano ^a   Manfroni, Giuseppe ^a   Fravolini, Arnaldo ^a   Raygada, Jose L ^b   Patel, Diixa ^b   Kaatz, Glenn W ^b   Cruciani, Gabriele ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[3 (BENZYLOXY)BENZYL]AMINO] 1 PHENYLPROPAN 1 OL; 3 [5 [(3 SEC BUTYL 2,4 DIOXO 1,3 THIAZOLIDIN 5 YLIDENE)METHYL]2 FURYL] 4 CHLOROBENZOIC ACID; 4 [[[3 CYANO 6 ETHYL 4 (TRIFLUOROMETHYL) 5,6,7,8 TETRAHYDROQUINOLIN 2 YL]THIO]METHYL]BENZOIC ACID; 4 METHYL N [2 (1 METHYL 1H PYRROL 2 YL) 1H BENZIMIDAZOL 5 YL]BENZENESULFONAMIDE; ANTIBIOTIC AGENT; CIPROFLOXACIN; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; DRUG SCREENING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZIMIDAZOLES; CIPROFLOXACIN; DATABASES, FACTUAL; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ETHIDIUM; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHENYL ETHERS; PROPANOLAMINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 78651073856     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1011963     Document Type: Article

References (78)

1. Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H. W.; Scheld, W. M.; Bartlett, J. G.; Edwards, J., Jr. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America Clin. Infect. Dis. 2008, 46, 155-164
2. Kumarasamy, K. K.; Toleman, M. A.; Walsh, T. R.; Bagaria, J.; Butt, F.; Balakrishnan, R.; Chaudhary, U.; Doumith, M.; Giske, C. G.; Irfan, S.; Krishnan, P.; Kumar, A. V.; Maharjan, S.; Mushtaq, S.; Noorie, T.; Paterson, D. L.; Pearson, A.; Perry, C.; Pike, R.; Rao, B.; Ray, U.; Sarma, J. B.; Sharma, M.; Sheridan, E.; Thirunarayan, M. A.; Turton, J.; Upadhyay, S.; Warner, M.; Welfare, W.; Livermore, D. M.; Woodford, N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Lancet Infect. Dis. 2010, 10, 597-602
3. Finks, J.; Wells, E.; Dyke, T. L.; Husain, N.; Plizga, L.; Heddurshetti, R.; Wilkins, M.; Rudrik, J.; Hageman, J.; Patel, J.; Miller, C. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007 Emerging Infect. Dis. 2009, 15, 943-945
4. Sievert, D. M.; Rudrik, J. T.; Patel, J. B.; McDonald, L. C.; Wilkins, M. J.; Hageman, J. C. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006 Clin. Infect. Dis. 2008, 46, 668-674
5. Diekema, D. J.; Jones, R. N. Oxazolidinone antibiotics Lancet 2001, 358, 1975-1982
6. Meka, V. G.; Gold, H. S. Antimicrobial resistance to linezolid Clin. Infect. Dis. 2004, 39, 1010-1015
7. Tsiodras, S.; Gold, H. S.; Sakoulas, G.; Eliopoulos, G. M.; Wennersten, C.; Venkataraman, L.; Moellering, R. C.; Ferraro, M. J. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 2001, 358, 207-208
8. Livermore, D. M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64, 29-36
9. Lomovskaya, O.; Zgurskaya, H. I.; Bostian, K. Bacterial Multidrug Transporters: Molecular and Clinical Aspects. In Transporters as Drug Carriers; Ecker, G. F.; Chiba, P., Eds.; Methods and Principles in Medicinal Chemistry, Vol. 44; Wiley-VCH: Weinheim, Germany, 2009; pp 121 - 157.
10. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited Microbiol. Mol. Biol. Rev. 2003, 67, 593-656
11. Piddock, L. J. Multidrug-resistance efflux pumps-not just for resistance Nat. Rev. Microbiol. 2006, 4, 629-636
12. Poole, K. Efflux pumps as antimicrobial resistance mechanisms Ann. Med. 2007, 39, 162-176
13. Guz, N. R.; Stermitz, F. R.; Johnson, J. B.; Beeson, T. D.; Willen, S.; Hsiang, J.; Lewis, K. Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationships J. Med. Chem. 2001, 44, 261-268
14. Payne, D. J. Desperately seeking new antibiotics Science 2008, 321, 1644-1645
15. Klein, E.; Smith, D. L.; Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 Emerging Infect. Dis. 2007, 13, 1840-1846
16. Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States JAMA, J. Am. Med. Assoc. 2007, 298, 1763-1771
17. Yoshida, H.; Bogaki, M.; Nakamura, S.; Ubukata, K.; Konno, M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones J. Bacteriol. 1990, 172, 6942-6949
18. Lomovskaya, O.; Lee, A.; Hoshino, K.; Ishida, H.; Mistry, A.; Warren, M. S.; Boyer, E.; Chamberland, S.; Lee, V. J. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa Antimicrob. Agents Chemother. 1999, 43, 1340-1346
19. Markham, P. N. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine Antimicrob. Agents Chemother. 1999, 43, 988-989
20. Ricci, V.; Tzakas, P.; Buckley, A.; Piddock, L. J. Ciprofloxacin- resistant Salmonella enterica serovar typhimurium strains are difficult to select in the absence of AcrB and TolC Antimicrob. Agents Chemother. 2006, 50, 38-42
21. Sabatini, S.; Kaatz, G. W.; Rossolini, G. M.; Brandini, D.; Fravolini, A. From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump J. Med. Chem. 2008, 51, 4321-4330
22. Michalet, S.; Cartier, G.; David, B.; Mariotte, A. M.; Dijoux-franca, M. G.; Kaatz, G. W.; Stavrid, M.; Gibbons, S. N -Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 1755-1758
23. Nargotra, A.; Sharma, S.; Koul, J. L.; Sangwan, P. L.; Khan, I. A.; Kumar, A.; Taneja, S. C.; Koul, S. Quantitative structure activity relationship (QSAR) of piperine analogs for bacterial NorA efflux pump inhibitors Eur. J. Med. Chem. 2009, 44, 4128-4135
24. German, N.; Kaatz, G. W.; Kernsa, R. J. Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps Bioorg. Med. Chem. Lett. 2008, 18, 1368-1373
25. Samosorn, S.; Bremner, J. B.; Ball, A.; Lewis, K. Synthesis of functionalized 2-aryl-5-nitro-1 H -indoles and their activity as bacterial NorA efflux pump inhibitors Bioorg. Med. Chem. 2006, 14, 857-865
26. Vidaillac, C.; Guillon, J.; Arpin, C.; Forfar-Bares, I.; Ba, B. B.; Grellet, J.; Moreau, S.; Caignard, D. H.; Jarry, C.; Quentin, C. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus Antimicrob. Agents Chemother. 2007, 51, 831-838
27. Chabert, J. F. d.; Marquez, B.; Neville, L.; Joucla, L.; Broussous, S.; Bouhours, P.; David, E.; Pellet-Rostaing, S.; Marquet, B.; Moreaub, N.; Lemaire, M. Synthesis and evaluation of new arylbenzo[ b ]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of Staphylococcus aureus Bioorg. Med. Chem. 2007, 15, 4482-4497
28. Marquez, B.; Neuville, L.; Moreau, N. J.; Genet, J. P.; Santos, A. F. d.; Andrade, M. C. C. d.; SantAna, A. E. G. Multidrug resistance reversal agent from Jatropha elliptica Phytochemistry 2005, 66, 1804-1811
29. German, N.; Wei, P.; Kaatz, G. W.; Kerns, R. J. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps Eur. J. Med. Chem. 2008, 43, 2453-2463
30. Pieroni, M.; Dimovska, M.; Brincat, J. P.; Sabatini, S.; Carosati, E.; Massari, S.; Kaatz, G. W.; Fravolini, A. From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps J. Med. Chem. 2010, 53, 4466-4480
31. Musumeci, R.; Speciale, A.; Costanzo, R.; Annino, A.; Ragusa, S.; Rapisarda, A.; Pappalardo, M. S.; Iauk, L. Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin Int. J. Antimicrob. Agents 2003, 22, 48-53
32. Chérigo, L.; Pereda-Miranda, R.; Fragoso-Serrano, M.; Jacobo-Herrera, N.; Kaatz, G. W.; Gibbons, S. Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides J. Nat. Prod. 2008, 71, 1037-1045
33. Stermitz, F. R.; Lorenz, P.; Tawara, J. N.; Zenewicz, L. A.; Lewis, K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5*-methoxyhydnocarpin, a multidrug pump inhibitor Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1433-1437
34. Pereda-Miranda, R.; Kaatz, G. W.; Gibbons, S. Polyacylated oligosaccharides from medicinal mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus J. Nat. Prod. 2006, 69, 406-409
35. Mullin, S.; Mani, N.; Grossman, T. H. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853) Antimicrob. Agents Chemother. 2004, 48, 4171-4176
36. Gibbons, S.; Oluwatuyi, M.; Kaatz, G. W. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus J. Antimicrob. Chemother. 2003, 51, 13-17
37. Zhang, L.; Ma, S. Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump ChemMedChem. 2010, 5, 811-822
38. Markham, P. N.; Westhaus, E.; Klyachko, K.; Johnson, M. E.; Neyfakh, A. A. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus Antimicrob. Agents Chemother. 1999, 43, 2404-2408
39. Takenouchi, T.; Tabata, F.; Iwata, Y.; Hanzawa, H.; Sugawara, M.; Ohya, S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated mutants of Staphylococcus aureus Antimicrob. Agents Chemother. 1996, 40, 1835-1842
40. Nargotra, A.; Koul, S.; Sharma, S.; Khan, I. A.; Kumar, A.; Thota, N.; Koul, J. L.; Taneja, S. C.; Qazi, G. N. Quantitative structure-activity relationship (QSAR) of aryl alkenyl amides/imines for bacterial efflux pump inhibitors Eur. J. Med. Chem. 2009, 44, 229-238
41. Kaatz, G. W.; Moudgal, V.; Seo, S.; Kristiansen, J. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus Antimicrob. Agents Chemother. 2003, 47, 719-726
42. Kaatz, G. W.; Moudgal, V.; Seo, S.; Hansen, J.; Kristiansen, J. Phenylpiperadine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus Int. J. Antimicrob. Agents 2003, 22, 254-261
43. Smith, E.; Kaatz, G.; Seo, S.; Wareman, N.; Williamson, E.; Gibbons, S. The phenolic diterpene totarol inhibitors multidrug efflux pump activity in Staphylococcus aureus Antimicrob. Agents Chemother. 2007, 51, 4480-4483
44. Sabatini, S.; Gosetto, F.; Manfroni, G.; Tabarrini, O.; Kaatz, G. W.; Cecchetti, V. Unpublished results.
45. Neyfakh, A. A. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein Antimicrob. Agents Chemother. 1992, 36, 484-485
46. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application J. Chem. Inf. Model. 2007, 47, 279-294
47. Cross, S.; Baroni, M.; Carosati, E.; Benedetti, P.; Clementi, S. FLAP: GRID molecular interaction fields in virtual screening. Validation using the DUD sata set J. Chem. Inf. Model. 2010, 50, 1442-1450
48. Carosati, E.; Cruciani, G.; Chiarini, A.; Budriesi, R.; Ioan, P.; Spisani, R.; Spinelli, D.; Cosimelli, B.; Fusi, F.; Frosini, M.; Matucci, R.; Gasparrini, F.; Ciogli, A.; Stephens, P. J.; Devlin, F. J. New calcium channel antagonists discovered by a multidisciplinary approach J. Med. Chem. 2006, 49, 5206-5216
49. ATP channels J. Med. Chem. 2007, 50, 2117-2126
50. Carosati, E.; Sforna, G.; Pippi, M.; Marverti, G.; Ligabue, A.; Guerrieri, D.; Piras, S.; Guaitoli, G.; Luciani, R.; Costi, M. P.; Cruciani, G. Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors Bioorg. Med. Chem. 2010, 18, 7773-7785
51. Carosati, E.; Budriesi, R.; Ioan, P.; Cruciani, G.; Fusi, F.; Frosini, M.; Saponara, S.; Gasparrini, F.; Ciogli, A.; Villani, C.; Stephens, P. J.; Devlin, F. J.; Spinelli, D.; Chiarini, A. Stereoselective behaviour of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl) pyrrolidine, a new L-type calcium channel blocker J. Med. Chem. 2009, 52, 6637-6648
52. Budriesi, R.; Cosimelli, B.; Ioan, P.; Ugenti, M. P.; Carosati, E.; Frosini, M.; Fusi, F.; Spisani, R.; Saponara, S.; Cruciani, G.; Novellino, E.; Spinelli, D.; Chiarini, A. L-type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives J. Med. Chem. 2009, 52, 2352-2362
53. Sciabola, S.; Stanton, R. V.; Mills, J. E.; Flocco, M. M.; Baroni, M.; Cruciani, G.; Perruccio, F.; Mason, J. S. High-throughput virtual screening of proteins using GRID molecular interaction fields J. Chem. Inf. Model. 2010, 50, 155-169
54. Goodford, P. J. A computational procedure for determining energetically favourable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
55. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field J. Med. Chem. 2004, 47, 5114-5125
56. The GRID package, version 22, is distributed from Molecular Discovery Ltd., http://www.moldiscovery.com.
57. 2 was calculated as the fraction of the total number of predicted molecules that were predicted in the correct activity class using the binary LDA model.
58. http://www.specs.net/.
59. Goldfarb, D. S. Method Using Lifespan-Altering Compounds for Altering the Lifespan of Eukaryotic Organisms, and Screening for Such Compounds. U.S. Pat. Appl. Publ. US2009163545 A1 20090625, 2009.
60. Wagh, S. B.; Yerande, S.; Patil, B. Preparation of 8-Chloro-11-(1- piperazinyl)-dibenz[ b, f ][1,4]oxazepines as Antipsychotic Agents. Indian Pat. Appl. 2005MU00365 A 20070420, 2007.
61. Shibo, J.; Debnath, A. S.; Lu, H. Anti-Viral Compositions Compromising Heterocyclic Substituted Phenyl Furans and Related Compounds. U.S. Pat. Appl. Publ. US 2006287319 A1 20061221, 2006.
62. Kaverina, N. V.; Lyskovtsev, V. V.; Senova, Z. P.; Gritsenko, A. N.; Ermakova, Z. I.; Skoldinov, A. P.; Carstens, E.; Wunderlich, H.; Stark, A. 5-(ω-Aminoacyl)-3-carbalkoxyamino-10,11-dihydro-5 H -dibenz[ b, f ]azepine Derivatives and Their Therapeutic Use. Fr. Demande, FR 2493314 A1 19820507, 1982.
63. Kaatz, G. W.; Seo, S. M. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus Antimicrob. Agents Chemother. 1997, 41, 2733-2737
64. Price, C. T. D.; Kaatz, G. W.; Gustafson, J. E. The multidrug efflux pump NorA is not required for salicylate-induced reduction in drug accumulation by Staphylococcus aureus Int. J. Antimicrob. Agents 2002, 20, 206-213
65. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
66. http://zinc.docking.org.
67. http://www.chemdiv.com.
68. http://www.chembridge.com.
69. http://www.vitasmlab.com.
70. http://www.keyorganics.ltd.uk.
71. Augustin, J.; Rosenstein, R.; Weiland, B.; Schneider, U.; Schnell, N.; Engelke, G.; Entian, K. D.; Götz, F. Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis Eur. J. Biochem. 1992, 204, 1149-1154
72. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A7, 7 th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, 2006.
73. Eliopoulos, G. M.; Moellering, R. C. J. Antimicrobial Combinations. In Antibiotics in Laboratory Medicine; Lorian, V., Ed.; Williams and Wilkins: Baltimore, MD, 1991; pp 432 - 492.
74. Kaatz, G. W.; Seo, S. M.; OBrien, L.; Wahiduzzaman, M.; Foster, T. J. Evidence for the existence of a multidrug efflux transporter distinct from norA in Staphylococcus aureus Antimicrob. Agents Chemother. 2000, 44, 1404-1406
75. Ahlström, M. M.; Ridderström, M.; Luthman, K.; Zamora, I. Virtual screening and scaffold hopping based on GRID molecular interaction fields J. Chem. Inf. Model. 2005, 45, 1313-1323
76. Lo Piparo, E.; Koehler, K.; Chana, A.; Benfenati, E. Virtual screening for aryl hydrocarbon receptor binding prediction J. Med. Chem. 2006, 49, 5702-5709
77. Carosati, E.; Budriesi, R.; Ioan, P.; Ugenti, M. P.; Frosini, M.; Fusi, F.; Corda, G.; Cosimelli, B.; Spinelli, D.; Chiarini, A.; Cruciani, G. Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening J. Med. Chem. 2008, 51, 5552-5565
78. Durán, A.; Zamora, I.; Pastor, M. Suitability of GRIND-based principal properties for the description of molecular similarity and ligand-based virtual screening J. Chem. Inf. Model. 2009, 49, 2129-2138